300497, opens and immediately hits daily limit, quarterly report surges over 22x!

robot
Abstract generation in progress

Today (March 24), the major indices of the A-share market opened higher and then weakened. By 10 a.m., all major indices turned red.

In the market, the pharmaceutical industry led the gains against the trend, with CRO concepts rising prominently. Fuxiang Pharmaceutical’s “20cm” hit the daily limit, Minohua also hit the limit, and Jin Kai Shengke, Bai Ao Saitu, and others rose over 8%.

Bank stocks generally rose, with Jiangsu Bank, Nanjing Bank, and Shanghai Rural Commercial Bank increasing over 3%.

Two stocks surge after releasing Q1 earnings forecast

Today, two companies announced their first-quarter earnings forecasts. Fuxiang Pharmaceutical (300497) expects a profit of 52 million to 75 million yuan in Q1, a year-on-year increase of 2222.67%–3250.01%. The company stated that benefiting from the continued improvement in the new energy industry, steady growth in power battery market demand, and rapid explosion in energy storage battery demand, upstream lithium battery material demand has continued to rise. The company’s lithium battery electrolyte additive business is performing well, with core products like VC and FEC increasing in both volume and price, driving significant year-on-year growth.

Yubo Xun expects a net profit of 38 million to 48 million yuan in Q1, a year-on-year increase of 79.23% to 126.4%.

In the early trading session today, both stocks opened significantly higher. Fuxiang Pharmaceutical hit the daily limit within the first minute of trading, and Yubo Xun once rose over 15%.

Two companies plan to raise funds through private placements

On March 24, two companies announced non-public offering plans.

Huazheng New Materials plans to issue no more than 47.03 million shares to no more than 35 specific targets, aiming to raise 1.2 billion yuan mainly for a high-grade copper-clad laminate production line with an annual capacity of 12 million sheets, and to supplement working capital.

Longtu Photomask plans to issue no more than 40.05 million shares to no more than 35 specific targets, aiming to raise 1.46 billion yuan mainly for the construction of a 40nm–28nm semiconductor mask production line.

The company stated that in China’s semiconductor mask industry, the high-end process fields of 40nm–28nm are still dominated by foreign manufacturers. Autonomous control of the photomask supply chain is an inevitable choice to ensure the security of China’s semiconductor industry. With the implementation of this fundraising project, it can effectively fill the gap in the domestic high-end semiconductor mask market, break foreign monopolies, promote coordinated development of China’s semiconductor industry chain, and accelerate the localization of semiconductor materials.

18 stocks see leverage funds increase holdings by over 100 million yuan

As of March 23, the total market financing balance was 2.6 trillion yuan, a decrease of 11.51 billion yuan from the previous trading day. This marks three consecutive trading days of decline in financing balance.

Specifically, on March 23, 1,557 stocks received net financing purchases, with 385 stocks exceeding 10 million yuan in net buy-in. Eighteen stocks had net financing purchases exceeding 100 million yuan. Xin Yisheng had the highest net buy-in at 805 million yuan; followed by Zhongji Xuchuang and Northern Rare Earth, with net purchases of 762 million yuan and 613 million yuan, respectively. Other stocks with high net buy-in amounts included Aixu Shares, Longi Green Energy, and Mingyang Smart.

Disclaimer: All information from Data Treasure does not constitute investment advice. The stock market carries risks; invest cautiously.

Proofread by: Su Huanwen

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin